Dr. Felix J. Baker has been the Chairman of the company since May 2022. Previously he served as a Director of the company from 2003. Dr. Baker is also a the founder of Baker Bros. Advisors LP, an advisory firm focused on investments in life science and biotechnology companies.

Mr. David R. Epstein has been the Chief Executive Officer and Director of the company since November 2022. Previously, he served as the Chief Executive Officer at Novartis Pharmaceuticals from 2010 to 2016. In addition, he also serves as a member of the board of directors for OPY Acquisition Corp. and Senti Biosciences, Inc.

Mr. Todd E. Simpson has been the Chief Financial Officer of the company since 2005. Prior to this role, he served as the Vice President, Finance and Administration and Chief Financial Officer at Targeted Genetics since October 2001. Mr. Simpson also served as the Vice President, Finance and Administration, and Chief Financial Officer of Aastrom Biosciences. Before that, he served at Integra Life Sciences Corporation and Telios Pharmaceuticals, Inc. in various financial leadership roles. Mr. Simpson also serves on the Boards of Directors of Washington Biotechnology and Biomedical Association (WBBA) and Aquinox Pharmaceuticals.

Ms. Jean I. Liu is the Chief Legal Officer of the company. Prior to this, she served as the General Counsel, Executive Vice President, Legal Affairs and Corporate Secretary since November 2014. Ms. Liu served as the Vice President of General Counsel at Halozyme Therapeutics. Before that, she served as the Chief Legal Officer and Corporate Secretary at Durect Corporation; and the Attorney at Pillsbury, Madison & Sutro and Venture Law Group.

Dr. Roger D. Dansey has been the President, Research and Development and Chief Medical Officer of the company since November 2022. Prior to this, he served as Senior Vice President at Merck Inc. Dr. Dansey also served as Vice President for Oncology Clinical Research at Gilead Sciences.